video
William Auyeng, MD, of Standford University and the VA Hospital in Palo Alto, CA, discusses peripheral eosonophil counts, and where he hopes to see the field in the future. (1:31)
Data from the FDA adverse event reporting system were reviewed to investigate reports of cardiovascular adverse events observed in patients receiving treatment with long-acting muscarinic receptor antagonists.
Early evidence suggests promise for a novel COPD treatment using autologous P63+ lung progenitor cell. This small study found the bronchoscopic transplantation of cultured P63+ cells to be safe and well-tolerated.
According to these findings, individuals with alpha-1 antitrypsin deficiency associated COPD report impairments in physical health but not mental health.
Heads up: These investigators found that TB survivors had a higher incidence of COPD and were more likely than control subjects to be hospitalized for COPD-related complications.